Search for content, post, videos

Kancera applies for new patent

The company has registered a patent application for new substances for cancer treatment that selectively inhibit the enzyme HDAC6.

The new patent application is based on HDAC6 inhibitors ability to affect mechanisms both inside of and outside of the cell nucleus. According to an announcement from the company it has been proven that HDAC6 has its large biological role in the regulation of the cancer nucleus ability to move and form metastasis.

In december 2013 Kancera announced a discovery of a new class of substances for the treatment of cancer and this type of substances has now been applied for patent.